Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk
This analysis shows that treatment recommendation for AI + OFS in premenopausal patients with HRpos/HER2neg eBC increased relevantly in the past years, reflecting latest guideline recommendations.
Authors
- Christian Rudlowski (ORCID: https://orcid.org/0000-0001-5763-9276)
- Peter Dall (ORCID: https://orcid.org/0000-0002-0565-7840)
- D Langanke
- Elmar Stickeler (ORCID: https://orcid.org/0000-0002-9715-7260)
- Peter A. Fasching (ORCID: https://orcid.org/0000-0003-4885-8471)
- Sara Y. Brucker (ORCID: https://orcid.org/0000-0001-5162-1542)
- Nina Ditsch (ORCID: https://orcid.org/0000-0001-7101-247X)
- Nadia Harbeck (ORCID: https://orcid.org/0000-0002-9744-7372)
- Caterina Iuliano
- Andreas D. Hartkopf (ORCID: https://orcid.org/0000-0003-1227-1118)
- Rachel Wuerstlein (ORCID: https://orcid.org/0000-0001-7268-0840)
- Y Baila
- Bahriye Aktas (ORCID: https://orcid.org/0000-0002-5474-051X)
- Erik Belleville
- Marc Thill (ORCID: https://orcid.org/0000-0002-8800-8044)
- Sabrina Uhrig
- Lothar Häberle
- Christian Roos
- Mustafa Aydoğdu (ORCID: https://orcid.org/0000-0002-1504-3674)
- Sabine Schmatloch (ORCID: https://orcid.org/0000-0002-0131-7515)
- Carolin Hammerle
- Christian Mann (ORCID: https://orcid.org/0000-0003-4553-7170)
- Jürgen Terhaag
- Maggie Banys‐Paluchowski
- Uwe Heilenkötter
- Alexander Hein (ORCID: https://orcid.org/0000-0003-2601-3398)
- Tanja Fehm (ORCID: https://orcid.org/0000-0002-4926-0108)
- Andreas Schneeweiß (ORCID: https://orcid.org/0000-0002-2429-4512)
- Manuel Hörner (ORCID: https://orcid.org/0000-0001-6934-992X)
- N. Deuerling
- Chloë Goossens (ORCID: https://orcid.org/0000-0002-0999-8562)
- Volkmar Müller (ORCID: https://orcid.org/0000-0002-6386-0900)
- Mignon-Denise Keyver-Paik
- Dorothea Fischer
- Martin Thoma
Institutions
- Universität Hamburg (DE)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospital Augsburg (DE)
- University Hospital Heidelberg (DE)
- Novartis (Germany) (DE)
- Universitätsklinikum Erlangen (DE)
- Düsseldorf University Hospital (DE)
- Krankenhaus vom Roten Kreuz (DE)
- Integrated Oncology (United States) (US)
- St. Elisabeth-Krankenhaus Leipzig (DE)
- Marienkrankenhaus Kassel (DE)
- St. Josefs Hospital (DE)
- Klinikum Itzehoe (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- National Center for Tumor Diseases (DE)
- University Hospital Schleswig-Holstein (DE)
- Olgahospital (DE)
- Klinikum Esslingen (DE)
- Klinikum Lüneburg (DE)
- University Children's Hospital Tübingen (DE)
- Klinikum Bielefeld (DE)
- Vogtland-Klinik (DE)
- Fraunhofer Project Centre Wolfsburg (DE)
- Agaplesion Markus Hospital (DE)
- Comprehensive Cancer Center Erlangen (DE)
- Klinikum Kassel (DE)
- Klinikum Bremen-Mitte (DE)
- Federal Highway and Transport Research Institute (DE)
- Klinikum Ernst von Bergmann (DE)
- Heinrich Heine University Düsseldorf (DE)
- Ludwig-Maximilians-Universität München (DE)
- RWTH Aachen University (DE)
- Leipzig University (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- The Breast
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1016/j.breast.2025.104458
- Citations
- 3
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- Novartis